摘要
背景/目的:二肽基肽酶-4的影响(DPP-4)对血浆脂联素浓度的抑制剂,脂肪源性激素与抗动脉粥样硬化和抗炎的特性是不确定的。一项系统回顾和荟萃分析的随机对照试验(RCT)研究了在人类中的这一联系。方法:在搜索PubMed MEDLINE、SCOPUS鉴定,和谷歌学术数据库(截至二月2015)之后,随机对照试验研究DPP-4抑制剂对血浆脂联素浓度的影响被确认。作为定量数据的合成方法,应用了随机效应模型和通用的逆方差法。进行了标准方法的荟萃回归,敏感性分析和发表偏向评估。结果:进行了八个带有九个治疗组的随机对照试验。Meta分析并没有显示出显著的综合效果DPP IV抑制剂对脂联素值的影响(weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88)。然而,在维格列汀试验子集观察到血浆脂联素浓度显著升高(WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010)而不是西他列汀(WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907)。在比较DPP-4抑制剂与安慰剂或不治疗试验的子集的血浆脂联素水平显著升高(WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001)而不使用降糖药物的子集作为比较),或使用其他降糖药(WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654)。通过荟萃回归分析,在治疗时间,没有显着的影响被发现。结论:DPP-4抑制剂导致显著增加血浆脂联素浓度的影响更大,维格列汀优于西格列汀。
关键词: 脂联素,心血管疾病,二肽基肽酶抑制剂,Meta分析,系统评价,2型糖尿病。
Current Medicinal Chemistry
Title:Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Volume: 23 Issue: 13
Author(s): Amirhossein Sahebkar, Valentina Ponzo, Simona Bo
Affiliation:
关键词: 脂联素,心血管疾病,二肽基肽酶抑制剂,Meta分析,系统评价,2型糖尿病。
摘要: Background/Objectives: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on plasma concentrations of adiponectin, a fat-derived hormone with anti-atherogenic and anti-inflammatory properties, is uncertain. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate this association in humans. Methods: RCTs investigating the impact of DPP-4 inhibitors on plasma adiponectin concentrations were identified after searching PubMed-Medline, SCOPUS, and Google Scholar databases (up to February 2015). As quantitative data synthesis methods, the random-effects model and the generic inverse variance method were applied. Standard methods of meta-regression, sensitivity analysis, and publication bias assessments were performed. Results: Eight RCTs with nine treatment-arms were included. Meta-analysis did not suggest a significant pooled effect of DDP-4 inhibitors on adiponectin values (weighed-mean-difference [WMD]: 0.19 μg/mL, 95%CI: -0.50, 0.88). However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with vildagliptin (WMD: 0.55 μg/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 μg/mL, 95%CI: -1.13, 1.00, p=0.907). There was a significant elevation of plasma adiponectin levels in the subset of trials comparing DPP-4 inhibitors versus placebo or no treatment (WMD: 0.74 μg/mL, 95%CI: 0.36, 1.12, p <0.001) but not in the subset using hypoglycemic drugs as comparators), or using other hypoglycemic drugs (WMD: -0.18 μg/mL, 95%CI: -0.99, 0.62, p=0.654). No significant effect was found for treatment duration, confirmed by meta-regression analyses. Conclusion: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is greater with vildagliptin than sitagliptin.
Export Options
About this article
Cite this article as:
Amirhossein Sahebkar, Valentina Ponzo, Simona Bo , Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Current Medicinal Chemistry 2016; 23 (13) . https://dx.doi.org/10.2174/0929867323666160405111354
DOI https://dx.doi.org/10.2174/0929867323666160405111354 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]
Current Pharmaceutical Design Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?
Current Vascular Pharmacology The Promotion of Mental Health: Role of the Family
Adolescent Psychiatry Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components
Current Vascular Pharmacology Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design